Serum Institute of India commits to manufacturing 1 bn doses of Oxford-AstraZeneca COVID-19 vaccine

Serum Insititute has applied for regulatory approvals to start human trials of the vaccine in India starting August 2020.

tech2 News Staff July 21, 2020 15:07:42 IST
Serum Institute of India commits to manufacturing 1 bn doses of Oxford-AstraZeneca COVID-19 vaccine

After promising results from the early trials of an experimental COVID-19 vaccine developed by the University of Oxford and AstraZeneca, the Serum Institute of India has announced a manufacturing partnership with the company for the vaccine.

The Institute has said in a recent statement that it will manufacture 1 billion doses of the vaccine, after getting the required regulatory approvals to do so. The Serum Institute of India will begin human trials for the AstraZeneca Oxford Vaccine from August, as per a report in the Times of India.

"We will...start human trials in India [of the Oxford-AstraZeneca vaccine] in August 2020. Based on the current situation and most recent updates on the clinical trials, we are hoping that [the vaccine] will be available towards the end of this year," Adar Poonawalla, CEO of Serum Institute of India, told Press Trust of India.

Serum Institute of India commits to manufacturing 1 bn doses of OxfordAstraZeneca COVID19 vaccine

Representational Image. Credit; U.S. Navy photo by Chief Petty Officer Anthony Sisti

AstraZeneca has already committed to making 2 billion doses of the vaccine, and has now partnered with SII to produce 1 billion more, as per the report.

The promising Phase 1/2 vaccine trials have likely caused SII to shift from their earlier statement, that it will begin manufacturing prior to approval, so as to be ready with enough volumes once the vaccine is cleared in the vaccine's final leg of trials, and by Indian regulators.

The experimental vaccine developed by Oxford University and AstraZeneca, which is going by the placeholder name AZD1222, uses an inactivated (harmless) form of the COVID-causing SARS-CoV-2 virus, which the immune system uses as target practice to fight off a future coronavirus infection.

Based on the data released by the phase one/phase two study in 1,077 healthy volunteers, the vaccine was found to trigger two unique, important immune responses to the virus. Scientists say this is a good sign for the experimental vaccine candidate, retaining its status as the front-runner in the global effort to find a working vaccine to prevent COVID-19 infection.

Also read: Early results from Oxford vaccine trial show it triggers a dual immune response against the virus

Updated Date:

also read

Male, elderly patients with severe COVID-19 may have higher levels of antibodies in their plasma, reveals study
Health

Male, elderly patients with severe COVID-19 may have higher levels of antibodies in their plasma, reveals study

Scientists said that a possible explanation for this could be that due to severe disease, the inflammatory response in the body gets accelerated, recruiting more B-cells to fight the infection. This consequently results in more antibody production

SADS-CoV: Swine acute diarrhea syndrome coronavirus could spread from pigs to humans, claims study
Health

SADS-CoV: Swine acute diarrhea syndrome coronavirus could spread from pigs to humans, claims study

The researchers created a synthetic clone of the SADS-CoV virus and infected human sample cells with this derivative recombinant SADS-CoV or rSADS-CoV to see if virus transmission, replication and in vitro gene expression was possible.

Australian study claims SARS-CoV-2 can stay on mobile screens, stainless steel and money for up to 28 days
Health

Australian study claims SARS-CoV-2 can stay on mobile screens, stainless steel and money for up to 28 days

The scientists stated that by increasing the temperature while maintaining the humidity, the virus can be cleared off the surfaces within 24 hours